Alessandro Rizzo

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 115

Top Venues

Future oncology (London, England)

Cancers

Immunotherapy

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Alessandro Rizzo, Francesca Ambrogio, Matteo Centonze, Annalisa Schirizzi, Giampiero De Leonardis, Rosalba D'Alessandro, Claudio Lotesoriere, Gianluigi Giannelli
Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. International journal of molecular sciences 25 (14) (2024)
Elsa Vitale, Alessandro Rizzo
Lifestyle Profiles of Italian Oncology Nurses according to Sex, Work Experience and Shift: An Exploratory Study. Diseases (Basel, Switzerland) 12 (3) (2024)
Alessandro Rizzo, Lucia Rinaldi, Raffaella Massafra, Antonio Cusmai, Deniz Can Guven, Daniele La Forgia, Agnese Latorre, Francesco Giotta
Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes. Future oncology (London, England) (2024)
Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Alessandro Rizzo, Francesca Ambrogio, Matteo Centonze, Annalisa Schirizzi, Giampiero De Leonardis, Rosalba D'Alessandro, Claudio Lotesoriere, Gianluigi Giannelli
Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. International journal of molecular sciences 25 (14) (2024)
Elsa Vitale, Alessandro Rizzo
Lifestyle Profiles of Italian Oncology Nurses according to Sex, Work Experience and Shift: An Exploratory Study. Diseases (Basel, Switzerland) 12 (3) (2024)
Taha Koray Sahin, Alessandro Rizzo, Sercan Aksoy, Deniz Can Guven
Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers 16 (10) (2024)
Elsa Vitale, Alessandro Rizzo
Lifestyle Profiles of Italian Oncology Nurses according to Sex, Work Experience and Shift: An Exploratory Study. Diseases (Basel, Switzerland) 12 (3) (2024)
Elsa Vitale, Alessandro Rizzo, Kazuki Santa, Emilio Jirillo
Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review. Biology 13 (5) (2024)
Elsa Vitale, Alessandro Rizzo, Kazuki Santa, Emilio Jirillo
Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review. Biology 13 (5) (2024)
Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Alessandro Rizzo, Francesca Ambrogio, Matteo Centonze, Annalisa Schirizzi, Giampiero De Leonardis, Rosalba D'Alessandro, Claudio Lotesoriere, Gianluigi Giannelli
Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. International journal of molecular sciences 25 (14) (2024)
Taha Koray Sahin, Alessandro Rizzo, Sercan Aksoy, Deniz Can Guven
Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers 16 (10) (2024)
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, Francesco Massari, Se Hoon Park, Maria T Bourlon, Alexandr Poprach, Mimma Rizzo, Hideki Takeshita, Patrizia Giannatempo, Andrey Soares, Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Carrozza, Halima Abahssain, Carlo Messina, Ray Manneh Kopp, Renate Pichler, Luigi Formisano, Deniz Tural, Francesco Atzori, Fabio Calabrò, Ravindran Kanesvaran, Sebastiano Buti, Matteo Santoni
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project. Targeted oncology (2024)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo
Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancer. Thoracic cancer (2023)
Vito Longo, Alessandro Rizzo, Annamaria Catino, Michele Montrone, Domenico Galetta
Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta-analysis of randomized controlled trials. Thoracic cancer (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Angela Dalia Ricci, Rosalba D'Alessandro, Alessandro Rizzo, Annalisa Schirizzi, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Claudio Lotesoriere, Gianluigi Giannelli
Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door? Immunotherapy (2023)
Domenica Antonia Bavaro, Annarita Fanizzi, Serena Iacovelli, Samantha Bove, Maria Colomba Comes, Cristian Cristofaro, Daniela Cutrignelli, Valerio De Santis, Annalisa Nardone, Fulvia Lagattolla, Alessandro Rizzo, Cosmo Maurizio Ressa, Raffaella Massafra
A Machine Learning Approach for Predicting Capsular Contracture after Postmastectomy Radiotherapy in Breast Cancer Patients. Healthcare (Basel, Switzerland) 11 (7) (2023)
Andrea Palloni, Silvia Bisello, Ilaria Maggio, Maria Massucci, Andrea Galuppi, Alessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, Giambattista Siepe, Alessio Giuseppe Morganti, Giovanni Brandi, Giorgio Frega
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma. Current oncology (Toronto, Ont.) 30 (5) (2023)
Annalisa Schirizzi, Giampiero De Leonardis, Vincenza Lorusso, Rossella Donghia, Alessandro Rizzo, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Gianluigi Giannelli, Angela Dalia Ricci, Rosalba D'Alessandro, Claudio Lotesoriere
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers 15 (8) (2023)
Annalisa Schirizzi, Giampiero De Leonardis, Vincenza Lorusso, Rossella Donghia, Alessandro Rizzo, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Gianluigi Giannelli, Angela Dalia Ricci, Rosalba D'Alessandro, Claudio Lotesoriere
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers 15 (8) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Rossana Franzin, Alessandra Stasi, Giuseppe De Palma, Angela Picerno, Claudia Curci, Serena Sebastiano, Monica Campioni, Antonella Cicirelli, Alessandro Rizzo, Vito Francesco Di Lorenzo, Paola Pontrelli, Giovanni Battista Pertosa, Giuseppe Castellano, Loreto Gesualdo, Fabio Sallustio
Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles. Cells 12 (12) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Annarita Fanizzi, Agnese Latorre, Domenica Antonia Bavaro, Samantha Bove, Maria Colomba Comes, Erika Francesca Di Benedetto, Federico Fadda, Daniele La Forgia, Francesco Giotta, Gennaro Palmiotti, Nicole Petruzzellis, Lucia Rinaldi, Alessandro Rizzo, Vito Lorusso, Raffaella Massafra
Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach. Cancer medicine (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Rossana Franzin, Alessandra Stasi, Giuseppe De Palma, Angela Picerno, Claudia Curci, Serena Sebastiano, Monica Campioni, Antonella Cicirelli, Alessandro Rizzo, Vito Francesco Di Lorenzo, Paola Pontrelli, Giovanni Battista Pertosa, Giuseppe Castellano, Loreto Gesualdo, Fabio Sallustio
Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles. Cells 12 (12) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Vito Longo, Alessandro Rizzo, Annamaria Catino, Michele Montrone, Domenico Galetta
Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta-analysis of randomized controlled trials. Thoracic cancer (2023)
Rossana Franzin, Alessandra Stasi, Giuseppe De Palma, Angela Picerno, Claudia Curci, Serena Sebastiano, Monica Campioni, Antonella Cicirelli, Alessandro Rizzo, Vito Francesco Di Lorenzo, Paola Pontrelli, Giovanni Battista Pertosa, Giuseppe Castellano, Loreto Gesualdo, Fabio Sallustio
Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles. Cells 12 (12) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Giacomo Nuvola, Alessandro Rizzo, Veronica Mollica, Francesco Massari
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem? Immunotherapy 14 (4) (2022)
Alessandro Rizzo, Angela Dalia Ricci
Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. International journal of molecular sciences 23 (19) (2022)
Alessandro Rizzo, Gennaro Palmiotti
SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate. Future oncology (London, England) 18 (11) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Rodolfo Montironi, Francesco Massari
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future oncology (London, England) 18 (6) (2022)
Matteo Righini, Veronica Mollica, Alessandro Rizzo, Gaetano La Manna, Francesco Massari
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. Journal of clinical medicine 11 (15) (2022)
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici, Giovanni Brandi
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina (Kaunas, Lithuania) 58 (11) (2022)
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, Francesco Giovannelli, Lucia Rinaldi, Andrea Misino, Gennaro Palmiotti
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future oncology (London, England) 18 (18) (2022)
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers 14 (10) (2022)
Alessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, Alessandro Di Federico, Deniz Can Guven, Suayib Yalcin, Giovanni Brandi
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. Journal of personalized medicine 12 (8) (2022)
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Future oncology (London, England) 18 (8) (2022)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma. The oncologist (2022)
Alessandro Rizzo, Riccardo Carloni, Giorgio Frega, Andrea Palloni, Alessandro Di Federico, Angela Dalia Ricci, Raffaele De Luca, Simona Tavolari, Giovanni Brandi
Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. Current oncology (Toronto, Ont.) 29 (7) (2022)
Giovanni Brandi, Alessandro Rizzo
IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? International journal of molecular sciences 23 (18) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Gennaro Palmiotti, Francesco Massari
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. Journal of clinical medicine 11 (4) (2022)
Alessandro Rizzo
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. British journal of cancer 127 (8) (2022)
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta-Caldarola, Gennaro Palmiotti
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward. Medicina (Kaunas, Lithuania) 58 (5) (2022)
Alessandro Rizzo
Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand? Future oncology (London, England) 18 (14) (2022)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of personalized medicine 12 (11) (2022)
Raffaella Massafra, Samantha Bove, Daniele La Forgia, Maria Colomba Comes, Vittorio Didonna, Gianluca Gatta, Francesco Giotta, Agnese Latorre, Annalisa Nardone, Gennaro Palmiotti, Davide Quaresmini, Lucia Rinaldi, Pasquale Tamborra, Francesco Alfredo Zito, Alessandro Rizzo, Annarita Fanizzi, Vito Lorusso
An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study. Cancers 14 (9) (2022)
Alessandro Rizzo
Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. Journal of clinical medicine 11 (13) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. Journal of clinical medicine 11 (21) (2022)
Alessandro Rizzo, Gennaro Palmiotti
Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block? Immunotherapy 14 (10) (2022)
Gennaro Gadaleta-Caldarola, Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Arianna Gadaleta-Caldarola, Stefania Infusino, Antonio Cusmai, Claudia Citrigno, Gennaro Palmiotti
Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Current oncology (Toronto, Ont.) 29 (10) (2022)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of personalized medicine 12 (11) (2022)
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Angela Dalia Ricci, Concetta Calabrò, Antonio Cusmai, Gennaro Gadaleta-Caldarola, Gennaro Palmiotti, Francesco Massari
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. Journal of personalized medicine 12 (5) (2022)
Alessandro Rizzo, Giovanni Brandi
FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center. JCO precision oncology 6 (2022)
Daniele La Forgia, Gaetano Paparella, Rahel Signorile, Francesca Arezzo, Maria Colomba Comes, Gennaro Cormio, Antonella Daniele, Annarita Fanizzi, Agnese Maria Fioretti, Gianluca Gatta, Miria Lafranceschina, Alessandro Rizzo, Gian Maria Zaccaria, Angelo Rosa, Raffaella Massafra
Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari. International journal of environmental research and public health 20 (1) (2022)
Daniele La Forgia, Gaetano Paparella, Rahel Signorile, Francesca Arezzo, Maria Colomba Comes, Gennaro Cormio, Antonella Daniele, Annarita Fanizzi, Agnese Maria Fioretti, Gianluca Gatta, Miria Lafranceschina, Alessandro Rizzo, Gian Maria Zaccaria, Angelo Rosa, Raffaella Massafra
Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari. International journal of environmental research and public health 20 (1) (2022)
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, Silvana Acquafredda, Giuseppe De Palma, Giovanni Brandi, Gennaro Palmiotti
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current oncology (Toronto, Ont.) 29 (2) (2022)
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers 14 (17) (2022)
Massimiliano Salati, Alessandro Rizzo
The Last Dance for Chemotherapy Intensification in Non-Asian Advanced Biliary Tract Cancers? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (12) (2022)
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Francesco Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells 11 (12) (2022)
Alessandro Rizzo
Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first-line treatment for advanced non-small cell lung cancer. Thoracic cancer 13 (4) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis. Immunotherapy 14 (8) (2022)
Daniele La Forgia, Gaetano Paparella, Rahel Signorile, Francesca Arezzo, Maria Colomba Comes, Gennaro Cormio, Antonella Daniele, Annarita Fanizzi, Agnese Maria Fioretti, Gianluca Gatta, Miria Lafranceschina, Alessandro Rizzo, Gian Maria Zaccaria, Angelo Rosa, Raffaella Massafra
Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari. International journal of environmental research and public health 20 (1) (2022)
Veronica Mollica, Francesco Massari, Alessandro Rizzo, Roberto Ferrara, Arjun K Menta, Jacob J Adashek
Genomics and Immunomics in the Treatment of Urothelial Carcinoma. Current oncology (Toronto, Ont.) 29 (5) (2022)
Daniele La Forgia, Gaetano Paparella, Rahel Signorile, Francesca Arezzo, Maria Colomba Comes, Gennaro Cormio, Antonella Daniele, Annarita Fanizzi, Agnese Maria Fioretti, Gianluca Gatta, Miria Lafranceschina, Alessandro Rizzo, Gian Maria Zaccaria, Angelo Rosa, Raffaella Massafra
Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari. International journal of environmental research and public health 20 (1) (2022)
Alessandro Rizzo
Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer. Thoracic cancer 13 (21) (2022)
Angela Dalia Ricci, Alessandro Rizzo, Fabiola Lorena Rojas Llimpe, Francesca Di Fabio, Dario de Biase, Karim Rihawi
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift? Cancers 13 (7) (2021)
Angela Dalia Ricci, Alessandro Rizzo
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer? Medicina (Kaunas, Lithuania) 57 (12) (2021)
Maria Massucci, Veronica Mollica, Alessandro Rizzo, Laura Ventrella, Ilaria Maggio, Lisa Manuzzi, Lidia Gatto, Giovanni Brandi, Francesco Massari
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines (Basel, Switzerland) 8 (1) (2021)
Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)". The oncologist 26 (5) (2021)
Alessandro Rizzo, Giovanni Brandi
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert review of gastroenterology & hepatology 15 (5) (2021)
Alessandro Rizzo
Use of granulocyte colony-stimulating factor for adult cancer patients: current issues and future directions. Future oncology (London, England) 17 (26) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. Journal of clinical medicine 10 (22) (2021)
Alessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, Angela Dalia Ricci, Ilaria Maggio, Andrea Marchetti, Matteo Rosellini, Matteo Santoni, Andrea Ardizzoni, Francesco Massari
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future oncology (London, England) 17 (20) (2021)
Alessandro Di Federico, Valentina Tateo, Claudia Parisi, Francesca Formica, Riccardo Carloni, Giorgio Frega, Alessandro Rizzo, Dalia Ricci, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals (Basel, Switzerland) 14 (7) (2021)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 13 (8) (2021)
Francesco Massari, Alessandro Rizzo, Veronica Mollica, Matteo Santoni
A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? Future oncology (London, England) 17 (15) (2021)
Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Alessandro Rizzo, Elisa Tassinari, Giacomo Nuvola, Alessia Cimadamore, Matteo Santoni, Michelangelo Fiorentino, Rodolfo Montironi, Francesco Massari
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? International journal of molecular sciences 22 (12) (2021)
Alessandro Rizzo, Maria Abbondanza Pantaleo, Annalisa Astolfi, Valentina Indio, Margherita Nannini
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST). Cancers 13 (4) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Francesco Massari
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future oncology (London, England) 18 (5) (2021)
Alessandro Rizzo, Giovanni Brandi
Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina (Kaunas, Lithuania) 57 (3) (2021)
Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy 13 (8) (2021)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future oncology (London, England) 17 (7) (2021)
Matteo Rosellini, Matteo Santoni, Veronica Mollica, Alessandro Rizzo, Alessia Cimadamore, Marina Scarpelli, Nadia Storti, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Treating Prostate Cancer by Antibody-Drug Conjugates. International journal of molecular sciences 22 (4) (2021)
Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look. Cancer control : journal of the Moffitt Cancer Center 27 (3) (2021)
Alessandro Rizzo, Alessandro Di Federico, Angela Dalia Ricci, Giorgio Frega, Andrea Palloni, Rachele Pagani, Simona Tavolari, Mariacristina Di Marco, Giovanni Brandi
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer control : journal of the Moffitt Cancer Center 27 (1) (2021)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Recent advances of immunotherapy for biliary tract cancer. Expert review of gastroenterology & hepatology 15 (5) (2021)
Alessandro Rizzo
Novel approaches for the management of biliary tract cancer: today and tomorrow. Expert opinion on investigational drugs 30 (4) (2021)
Veronica Mollica, Andrea Marchetti, Matteo Rosellini, Giacomo Nuvola, Alessandro Rizzo, Matteo Santoni, Alessia Cimadamore, Rodolfo Montironi, Francesco Massari
An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International journal of molecular sciences 22 (24) (2021)
Alessandro Rizzo
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas, Lithuania) 57 (5) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Giada Grilli, Alba Greco, Rodolfo Montironi, Andrea Ardizzoni, Francesco Massari
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy 13 (9) (2021)
Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
DNA damage response alterations in gastric cancer: knocking down a new wall. Future oncology (London, England) 17 (8) (2021)
Margherita Nannini, Alessandro Rizzo, Valentina Indio, Angela Schipani, Annalisa Astolfi, Maria Abbondanza Pantaleo
Targeted therapy in SDH-deficient GIST. Therapeutic advances in medical oncology 13 (2021)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future oncology (London, England) 16 (32) (2020)

Alessandro Rizzo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Alessandro Rizzo